Leukocyte transmigration across endothelial and extracellular matrix protein barriers in liver ischemia/reperfusion injury

Current Opinion in Organ Transplantation

Volumn 16, Issue 1, 2011, Pages 34-40

  Coito, Ana J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adhesion molecules; fibronectin; liver ischemia and reperfusion injury; matrix metalloproteinases

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR6; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FREE RADICAL; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PADGEM PROTEIN; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ARTICLE; CYTOKINE RELEASE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; LEUKOCYTE MIGRATION; LIVER ISCHEMIA; LIVER TRANSPLANTATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REPERFUSION INJURY; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX PROTEINS; HUMANS; LEUKOCYTES; LIVER; MATRIX METALLOPROTEINASE 9; REPERFUSION INJURY;

EID: 78751633268     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328342542e     Document Type: Article

References (106)

1. Howard TK, Klintmalm GB, Cofer JB, et al. The influence of preservation injury on rejection in the hepatic transplant recipient. Transplantation 1990; 49:103-107.
2. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20:829-838.
3. Henderson JM. Liver transplantation and rejection: an overview. Hepatogastroenterology 1999; 46 (Suppl 2):1482-1484.
4. Nocito A, El Badry AM, Clavien PA. When is steatosis too much for transplantation? J Hepatol 2006; 45:494-499.
5. de Rougemont O, Dutkowski P, Clavien PA. Biological modulation of liver ischemia-reperfusion injury. Curr Opin Organ Transplant 2010; 15:183-189.
6. Lentsch AB, Kato A, Yoshidome H, et al. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology 2000; 32:169-173. (Pubitemid 30614647)
7. Basbaum CB, Werb Z. Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol 1996; 8:731-738.
8. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996; 88:3259-3287.
9. Ley K. The role of selectins in inflammation and disease. Trends Mol Med 2003; 9:263-268.
10. Huang K-S, Graves, BJ, Wolitzky BA. The selectins: initiators of leukocyte endothelial adhesion. Harwood Academic Publishers; 1997. pp. 1-30.
11. Grailer JJ, Kodera M, Steeber DA. L-selectin: role in regulating homeostasis and cutaneous inflammation. J Dermatol Sci 2009; 56:141-147.
12. Sperandio M, Gleissner CA, Ley K. Glycosylation in immune cell trafficking. Immunol Rev 2009; 230:97-113.
13. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J 1995; 9:866-873.
14. McEver RP. Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol 2002; 14:581-586.
15. Witz IP. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev 2008; 27:19-30.
16. Atkinson C, Zhu H, Qiao F, et al. Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol 2006; 177:7266-7274.
17. Xia L, Sperandio M, Yago T, et al. P-selectin glycoprotein ligand-1-deficient mice have impaired leukocyte tethering to E-selectin under flow. J Clin Invest 2002; 109:939-950.
18. Hidalgo A, Peired AJ, Wild MK, et al. Complete identification of E-selectin ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD44. Immunity 2007; 26:477-489.
19. Yago T, Shao B, Miner JJ, et al. E-selectin engages PSGL-1 and CD44 through a common signaling pathway to induce integrin alphaLbeta2- mediated slow leukocyte rolling. Blood 2010; 116:485-494.
20. Patel KD, Cuvelier SL, Wiehler S. Selectins: critical mediators of leukocyte recruitment. Semin Immunol 2002; 14:73-81.
21. Cai YH, Alvarez A, Alcaide P, et al. Abrogation of functional selectin-ligand expression reduces migration of pathogenic CD8 T cells into heart. J Immunol 2006; 176:6568-6575.
22. Lange-Sperandio B, Cachat F, Thornhill BA, Chevalier RL. Selectins mediate macrophage infiltration in obstructive nephropathy in newborn mice. Kidney Int 2002; 61:516-524.
23. Garcia-Criado FJ, Toledo-Pereyra LH, Lopez-Neblina F, et al. Role of P-selectin in total hepatic ischemia and reperfusion. J Am Coll Surg 1995; 181:327-334.
24. Dulkanchainun TS, Goss JA, Imagawa DK, et al. Reduction of hepatic ischemia/reperfusion injury by a soluble P-selectin glycoprotein ligand-1. Ann Surg 1998; 227:832-840.
25. Tsuchihashi S, Fondevila C, Shaw GD, et al. Molecular characterization of rat leukocyte P-selectin glycoprotein ligand-1 and effect of its blockade: protection from ischemia-reperfusion injury in liver transplantation. J Immunol 2006; 176:616-624.
26. Young CS, Palma JM, Mosher BD, et al. Hepatic ischemia/reperfusion injury in P-selectin and intercellular adhesion molecule-1 double-mutant mice. Am Surg 2001; 67:737-744.
27. Wong J, Johnston B, Lee SS, et al. A minimal role for selectins in the recruitment of leukocytes into the inflamed liver microvasculature. J Clin Invest 1997; 99:2782-2790.
28. Wyllie S, Barshes NR, Gao FQ, et al. Failure of P-selectin blockade alone to protect the liver from ischemia-reperfusion injury in the isolated bloodperfused rat liver. World J Gastroenterol 2008; 14:6808-6816.
29. Gaboury JP, Kubes P. Reductions in physiologic shear rates lead to CD11/ CD18-dependent, selectin-independent leukocyte rolling in vivo. Blood 1994; 83:345-350.
30. Lee WY, Kubes P. Leukocyte adhesion in the liver: distinct adhesion paradigm from other organs. J Hepatol 2008; 48:504-512.
31. Hayashi M, Tokunaga Y, Fujita T, et al. The effects of cold preservation on steatotic graft viability in rat liver transplantation. Transplantation 1993; 56:282-287.
32. Gao W, Connor HD, Lemasters JJ, et al. Primary nonfunction of fatty livers produced by alcohol is associated with a new, antioxidant-insensitive free radical species. Transplantation 1995; 59:674-679.
33. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21:105-113.
34. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004; 25:75-84.
35. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354:610-621.
36. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood 2005; 105:4191-4199.
37. Luissint AC, Lutz PG, Calderwood DA, et al. JAM-L-mediated leukocyte adhesion to endothelial cells is regulated in cis by alpha4beta1 integrin activation. J Cell Biol 2008; 183:1159-1173.
38. Oo YH, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun 2010; 34:45-54.
39. Wasmuth HE, Tacke F, Trautwein C. Chemokines in liver inflammation and fibrosis. Semin Liver Dis 2010; 30:215-225.
40. Seki E, De Minicis S, Inokuchi S, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009; 50:185-197.
41. Bamboat ZM, Balachandran VP, Ocuin LM, et al. Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology 2010; 51:621-632.
42. Lentsch AB, Yoshidome H, Cheadle WG, et al. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC. Hepatology 1998; 27:1172-1177.
43. Mosher B, Dean R, Harkema J, et al. Inhibition of Kupffer cells reduced CXC chemokine production and liver injury. J Surg Res 2001; 99:201-210.
44. Mukaida N, Hishinuma A, Zachariae CO, et al. Regulation of human interleukin gene expression and binding of several other members of the intercrine family to receptors for interleukin-8. Adv Exp Med Biol 1991; 305:31-38.
45. Kockritz-Blickwede M, Rohde M, Oehmcke S, et al. Immunological mechanisms underlying the genetic predisposition to severe Staphylococcus aureus infection in the mouse model. Am J Pathol 2008; 173:1657-1668.
46. Hamada T, Tsuchihashi S, Avanesyan A, et al. Cyclooxygenase-2 deficiency enhances th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury. J Immunol 2008; 180:1843-1853.
47. Tessier PA, Naccache PH, Clark-Lewis I, et al. Chemokine networks in vivo: involvement of C-X-C and C-C chemokines in neutrophil extravasation in vivo in response to TNF-alpha. J Immunol 1997; 159:3595-3602.
48. Hokeness KL, Deweerd ES, Munks MW, et al. CXCR3-dependent recruitment of antigen-specific T lymphocytes to the liver during murine cytomegalovirus infection. J Virol 2007; 81:1241-1250.
49. Heydtmann M, Adams DH. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology 2009; 49:676-688.
50. Heydtmann M, Lalor PF, Eksteen JA, et al. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 2005; 174:1055-1062.
51. Omenetti A, Syn WK, Jung Y, et al. Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology 2009; 50:518-527.
52. Diamond MS, Springer TA. The dynamic regulation of integrin adhesiveness. Curr Biol 1994; 4:506-517.
53. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110:673-687.
54. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 2010; 11:288-300.
55. Moyano JV, Carnemolla B, Dominguez-Jimenez C, et al. Fibronectin type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated alpha4beta1 and alpha4beta7 integrins. J Biol Chem 1997; 272:24832-24836.
56. Liao YF, Gotwals PJ, Koteliansky VE, et al. The EIIIA segment of fibronectin is a ligand for integrins alpha9beta1 and alpha4beta1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J Biol Chem 2002; 277:14467-14474.
57. Osborn L, Vassallo C, Browning BG, et al. Arrangement of domains, and amino acid residues required for binding of vascular cell adhesion molecule-1 to its counter-receptor VLA-4 (alpha4beta1). J Cell Biol 1994; 124:601-608.
58. Jarnagin WR, Rockey DC, Koteliansky VE, et al. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 1994; 127:2037-2048.
59. Amersi F, Shen XD, Moore C, et al. Fibronectin-alpha4beta1 integrinmediated blockade protects genetically fat Zucker rat livers from ischemia/ reperfusion injury. Am J Pathol 2003; 162:1229-1239.
60. Coito AJ, de Sousa M, Kupiec-Weglinski JW. Fibronectin in immune responses in organ transplant recipients. Dev Immunol 2000; 7:239-248.
61. Maurer LM, Tomasini-Johansson BR, Mosher DF. Emerging roles of fibronectin in thrombosis. Thromb Res 2010; 125:287-291.
62. Hindmarsh EJ, Marks RM. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J Immunol 1998; 160:6128-6136.
63. Sjoberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol 2009; 30:83-90.
64. Berlin C, Bargatze RF, Campbell JJ, et al. alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 1995; 80:413-422.
65. OConnor P. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther 2007; 7:123-136.
66. Fiorino G, Correale C, Fries W, et al. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Rev Clin Immunol 2010; 6:567-572.
67. Man S, Tucky B, Bagheri N, et al. alpha4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions. J Neuroimmunol 2009; 210:92-99.
68. Moore C, Shen XD, Gao F, et al. Fibronectin-{alpha}4{beta}1 integrin interactions regulate metalloproteinase-9 expression in steatotic liver ischemia and reperfusion injury. Am J Pathol 2007; 170:567-577.
69. Lalor PF, Edwards S, McNab G, et al. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol 2002; 169:983-992.
70. Jaeschke H, Hasegawa T. Role of neutrophils in acute inflammatory liver injury. Liver Int 2006; 26:912-919. (Pubitemid 44323408)
71. Casillas-Ramirez A, Mosbah IB, Ramalho F, et al. Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation. Life Sci 2006; 79:1881-1894.
72. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463-516.
73. Lohr KM, Kurth CA, Xie DL, et al. The amino-terminal 29- and 72-Kd fragments of fibronectin mediate selective monocyte recruitment. Blood 1990; 76:2117-2124.
74. Lee MH, Murphy G. Matrix metalloproteinases at a glance. J Cell Sci 2004; 117:4015-4016.
75. Woessner JF Jr. MMPs and TIMPs: an historical perspective. Mol Biotechnol 2002; 22:33-49.
76. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010; 20:161-168.
77. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000; 279:G245-G249.
78. Opdenakker G, Masure S, Grillet B, Van Damme J. Cytokine-mediated regulation of human leukocyte gelatinases and role in arthritis. Lymphokine Cytokine Res 1991; 10:317-324.
79. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274:21491-21494.
80. Yoshizaki T, Sato H, Furukawa M, Pagano JS. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci U S A 1998; 95:3621-3626.
81. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-174.
82. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006; 26:299-307.
83. Tchetverikov I, Lard LR, DeGroot J, et al. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003; 62:1094-1099.
84. Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998; 121:2327-2334.
85. Faber-Elmann A, Sthoeger Z, Tcherniack A, et al. Activity of matrix metalloproteinase-is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 2002; 127:393-398.
86. Gu Z, Kaul M, Yan B, et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002; 297:1186-1190.
87. Rylski M, Amborska R, Zybura K, et al. Yin Yang 1 is a critical repressor of matrix metalloproteinase-9 expression in brain neurons. J Biol Chem 2008; 283:35140-35153.
88. Kuyvenhoven JP, Ringers J, Verspaget HW, et al. Serum matrix metalloproteinase MMP-2 and MMP-9 in the late phase of ischemia and reperfusion injury in human orthotopic liver transplantation. Transplant Proc 2003; 35:2967-2969.
89. Kuyvenhoven JP, Molenaar IQ, Verspaget HW, et al. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury. Thromb Haemost 2004; 91:506-513.
90. Kuyvenhoven JP, Verspaget HW, Gao Q, et al. Assessment of serum matrix metalloproteinases MMP-2 and MMP-9 after human liver transplantation: increased serum MMP-9 level in acute rejection. Transplantation 2004; 77:1646-1652.
91. Cursio R, Mari B, Louis K, et al. Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J 2002; 16:93-95.
92. Hamada T, Fondevila C, Busuttil RW, Coito AJ. Metalloproteinase-9 deficiency protects against hepatic ischemia/reperfusion injury. Hepatology 2008; 47:186-198.
93. Ma ZY, Qian JM, Rui XH, et al. Inhibition of matrix metalloproteinase-9 attenuates acute small-for-size liver graft injury in rats. Am J Transplant 2010; 10:784-795.
94. Le NT, Xue M, Castelnoble LA, Jackson CJ. The dual personalities of matrix metalloproteinases in inflammation. Front Biosci 2007; 12:1475-1487.
95. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost 1999; 82:1730-1735.
96. Itoh T, Matsuda H, Tanioka M, et al. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 2002; 169:2643-2647.
97. Garg P, Rojas M, Ravi A, et al. Selective ablation of matrix metalloproteinase-exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. J Immunol 2006; 177:4103-4112.
98. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005; 1755:37-69.
99. McQuibban GA, Gong JH, Tam EM, et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000; 289:1202-1206.
100. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007; 26:717-724.
101. Fondevila C, Shen XD, Duarte S, et al. Cytoprotective effects of a cyclic RGD peptide in steatotic liver cold ischemia and reperfusion injury. Am J Transplant 2009; 9:2240-2250.
102. Hamada T, Duarte S, Tsuchihashi S, et al. Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury. Am J Pathol 2009; 174: 2265-2277.
103. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13:555-562.
104. Mackay CR. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat Immunol 2008; 9:988-998.
105. Friedl P, Weigelin B. Interstitial leukocyte migration and immune function. Nat Immunol 2008; 9:960-969.
106. Nourshargh S, Hordijk PL, Sixt M. Breaching multiple barriers: leukocyte motility through venular walls and the interstitium. Nat Rev Mol Cell Biol 2010; 11:366-378.